At-home Rystiggo infusion safe; most MG patients prefer self-care
Rystiggo (rozanolixizumab-noli) can be safely self-administered by people with myasthenia gravis (MG), according to data from a Phase 3 clinical trial. Based on these findings, at-home administration of Rystiggo was authorized earlier in 2025 in Japan and Europe. The work was funded by UCB, the company that sells Rystiggo.